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BURDEN 2020—Burden of
disease in Germany at the
national and regional level
All societies are subject to continuous
demographic changes and shifts in the
spectrum of the diseases affecting public
health. These developments are accom-
panied by population aging. Epidemio-
logical transitions resulting from control
ofmanyacute infectionshave beendomi-
natedbyashifttowardsnon-communica-
ble diseases (NCD) and marked changes
within the spectrum of NCDs. Stake-
holders in public health, including politi-
cians, face the task of assessing whether
publichealthactivitieshavebeensuccess-
ful and which diseases, injuries and risk
factors require amore targeted approach.
The allocation of research funds can de-
pend on assessments of these health is-
sues, as can the planning of major re-
forms, including those that take place in
the health sector. Such assessments need
to be based on reliable data and the best
available evidence. Moreover, they need
to enable diseases to be ranked accord-
ing to their relative priority and provide
information on developments over time.
Priority should not only be placed on the
incidence or prevalence of diseases but
also on the actual impact that the condi-
tions in question have on public health.
Although somediseasesmay tend tohave
less harmful effects, othersmighthave se-
rious consequences for individuals, if not
for the entire population. Even among
themost prevalent diseases, there are dif-
ferences in disease severity regarding the
consequences.
One approach that takes these chal-
lenges into account is the burden of
disease. This concept is being promi-
nently implemented as part of the Global
Burden of Disease (GBD) study. Based
on the International Statistical Classifi-
cation of Diseases and Related Health
Problems (ICD-10) the GBD study uses
disability-adjusted life years (DALY) to
combine mortality (deaths), frequency
(prevalence) and the severity (disability)
of a disease into a single coherent sum-
mary measure. This enables the relative
importance of particular diseases to be
compared, and proportions can be at-
tributed to a selected set of risk factors.
The project “BURDEN 2020—Burden
of disease in Germany at the national
and regional level” will use, adapt and
expand the GBD study approach. It is
aimed at fostering the acceptance of the
burden of disease approach in Germany
by using a broader data pool as part of
the assessment process and by taking
into account specific national challenges,
such as the implementation of regional
analyses. The key benefits of BURDEN
2020 will be:
4 The establishment of an informa-
tional system and a tool for the
visualization of the burden of disease
in Germany.
4 The evaluation and ranking of im-
portant diseases according to their
impact on public health.
4 The attribution of diseases and
injuries to key risk factors.
4 Regional analyses to illustrate the
benefits of sub-national estimates.
4 The establishment of a non-inter-
est-guided basis for health policy
planning.
The aim of this article is to describe the
potential of the BURDEN 2020 project
in more detail. It begins by introducing
the burden of disease approach before
presenting the potential benefits that can
be expected from BURDEN 2020. This
discussion is embedded in the context of
the experiences already gained by other
European countries. Finally, the article
outlines the project’s study design before
describing its structure and its principal
data pool.
Burden of disease: the concept,
challenges and previous studies
A concept for quantifying the
health of a population
Measuring the health of a population is
an essential means of identifying the ma-
jor drivers of ill health and highlighting
potential areas where prevention and in-
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 9 · 2018 1159
Aus den Herausgeberinstituten
Fig. 19 Disability-ad-
justed life years for Ger-
many in 2016 [6]
terventions can yield health benefits for
the entire population. The GBD study
was introduced in the late 1980s with the
aim of measuring global health. It was
the first in public health history to shed
light on thediseases, injuries and risk fac-
tors that contribute to the mortality and
morbidity of the global population [1].
TheWorld Health Organization, the cus-
todian of the GBD study, has performed
several updates of the global assessment.
After the 2010 study was published in
a special issue ofThe Lancet in 2012, the
Institute for Health Metrics and Evalua-
tion (IHME) took on the task of updating
the GBD study [2–4]. Researchers at the
IHME developed advanced methods to
combine fragmented data and to fill crit-
ical data gaps. The results of the GBD
study are provided by user-friendly tools
thatpresent thedata as charts and images.
The latest GBD study (2016) provides es-
timates for 195 countries/territories, and
333 diseases and injuries for the time
period ranging from 1990 to 2016 [5].
Since 2015, the IHME has been provid-
ing yearly updates, adding new data to
the models and recalculating the results
based on the improved methodology.
TheGBDstudyuses several indicators
to describe health status and cover the
impact of mortality and morbidity. The
study uses mortality statistics, informa-
tion on age at death and life expectancy
at this age to calculate what are referred
to as the years of life lost due to prema-
ture death (YLL).Combined information
on disease prevalence is used to estimate
the number of years lived with disability
(YLD) for calculations of morbidity. In
this calculation, the prevalence of sin-
gle diseases is adjusted for severity us-
ing disability weighting. Information on
prevalence stems from population-based
surveys or routine data, whereas infor-
mation on the severity distributions and
disability weighting is gathered from in-
ternational surveys [5]. The sum of both
YLL and YLD provides a summary mea-
sure of population health called disabil-
ity-adjusted life years (DALYs). This was
introduced in the first GBD study and
is used in several global, national and
even sub-national assessments to quan-
tify health losses among specific popu-
lations.
The GBD study also provides results
about the burden of disease in Germany.
The results forGermany are not currently
broken down into sub-national regional
units; however, treemaps are one of the
key tools that can be used to browse
through the GBD study results (. Fig. 1).
The outer square represents the total dis-
ease burden; the inner segments depict
the proportion taken up by non-com-
municable diseases (blue), communica-
ble, maternal, perinatal and nutritional
diseases (red) and injuries (green). The
results for Germany show that non-com-
municable diseases cause the largest bur-
den of disease, with only a small propor-
tion resulting from infectious diseases or
injuries. The top three causes of DALYs
in 2016were ischemic heart disease, back
and neck pain and diseases of the sense
organs.
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Abstract
Background. Evidence-based policy measures
need non-interest-guided information about
the health status of a population and the
diseases that affect the population the most.
In such cases, a national burden of disease
study can provide reliable insights at the
regional level.
Aim. This article presents the potential of
the BURDEN 2020 project and its expected
outcome for Germany at the national and
regional level.
Methods. The BURDEN 2020 project uses
several indicators including years of life lost
(YLL) to cover the impact of mortality and
years lived with disability (YLD) to cover
morbidity. The sum of both is the measure of
population health called disability adjusted
life years (DALY).
Results. The study ranks individual diseases
and risk factors based on their impact on
population health. The burden of disease
approach is assumed to be sensitive to
subnational differences and may generate
immediate benefits for regional planning.
The BURDEN 2020 study will pilot a national
burden of disease study for Germany that will
later be transformed into a continuous data
processing and visualization tool. This is done
by using, modifying and supplementing the
methodology employed by the Global Burden
of Disease (GBD) study to better fit the needs
of health policy in Germany. This study is
aimed at calculating the disease burden for up
to 17 preselected diseases. Furthermore, the
estimates of burden of disease are attributed
to a selected set of risk factors.
Conclusion. The Burden 2020 study will
provide the results of a new, health-related
data processing system to the public. This
includes a noninterest-guided presentation of
the burden of disease (DALY) in Germany at
the national and regional level.
Keywords
Burden of disease · Disability adjusted life
years · Non-communicable diseases · Health
policy planning · Regional prevalence
BURDEN 2020 – Krankheitslast in Deutschland auf nationaler und regionaler Ebene
Zusammenfassung
Hintergrund. Evidenzbasierte Politikmaßnah-
men benötigen unabhängige Informationen
über den Gesundheitszustand einer Bevölke-
rung und die Erkrankungen, von denen die
Bevölkerung am meisten betroffen ist. Hier
kann eine nationale Krankheitslaststudie zu
verlässlichen Erkenntnissen auf regionaler
Ebene beitragen.
Ziel. Dieser Artikel beschreibt das Potenzial
des Projekts BURDEN 2020 und seine
erwarteten Ergebnisse für Deutschland auf
nationaler und regionaler Ebene.
Methoden. BURDEN 2020 verwendet mehrere
Indikatoren, darunter „years of life lost“ (YLLs,
durch vorzeitigen Tod verlorene Lebensjahre),
um die Auswirkungen der Mortalität zu
erfassen und „years lived with disability“
(YLDs, mit Krankheit/Behinderung verbrachte
Lebensjahre) um die Morbidität abzubilden.
Die Summebeider Indikatoren gibt Aufschluss
über die Gesundheit der Bevölkerung
(„disability-adjusted life years“, DALYs).
Ergebnisse. Die Studie ordnet einzelne
Krankheiten und Risikofaktoren nach ihrem
Einfluss auf die Gesundheit der Bevölkerung.
Die Krankheitslast unterliegt regionalen
Unterschieden und kann unmittelbare Vorteile
für die Planung leisten. BURDEN 2020 pilotiert
eine nationale Krankheitslaststudie für
Deutschland, die später in ein kontinuierliches
Datenverarbeitungs- und Visualisierungstool
überführt werden soll. Dazu wird die Methodik
der Global-Burden-of-Disease-Studie genutzt
und modifiziert, um den Bedürfnissen
der Gesundheitspolitik in Deutschland
besser gerecht zu werden. Ziel ist, die
Krankheitslast für bis zu 17 ausgewählte
Krankheiten zu berechnen. Den Schätzungen
der Krankheitslast werden ausgewählte
Risikofaktoren zugeordnet.
Schlussfolgerung. Burden 2020 wird die Er-
gebnisse eines neuen, gesundheitsbezogenen
Datenverarbeitungssystemsder Öffentlichkeit
zur Verfügung stellen. Dazu gehört eine
interessenunabhängige Darstellung der




Lebensjahre · Nicht-übertragbare Krank-
heiten · Gesundheitspolitische Planung ·
Regionale Prävalenz
With respect to data availability and
quality, the models would ideally be
guided by strong national or even sub-
national data; however, data are some-
times unavailable for certain diseases,
injuries, years or countries. In these
cases, the IHME uses mathematical
models to overcome the problem of
missing data; however, data privacy re-
strictions mean that the IHME is unable
to use all of the available national and
sub-national data sources. Claims data,
for example, can be helpful in modelling
disease prevalence but are only readily
available to the national authorities.
Comparisons of GBD study figures
with statistics from the German
national level
Due to the study data that were selected
and specificmodelling processes, certain
figures published by the IHME can devi-
ate substantially from Germany’s official
statistics. This leads to discussion about
the external validityof the IHME’sfigures
and hampers the use of these statistics
at the German national level. For exam-
ple, the GBD study 2015 estimated for
Germany in terms of all-cause mortality
899,610 deaths (95% Uncertainty Inter-
val [UI] 850,327–951,882), which is far
lowerthanthe925,200deathsrecordedby
Germany’s national health reporting sys-
tem. The German federal health report-
ing systemplaces aparticular focusondi-
abetes (ICD-10: E10–E14) and recorded
24,400 deaths in 2015 [7]. Despite the
fact that the GBD study includes addi-
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Fig. 29 BURDEN2020. Ini-
tiating and sustaining a na-





tional ICD codes for diabetes, it provided
an estimate of just 20,527 deaths (95%
UI: 18,831–22,365). As such, the figures
from the national level were not within
the bounds of uncertainty ascribed to
the GBD study’s estimate. Furthermore,
diabetes-related deaths can be underes-
timated in the cause of deaths statistics
as complications and comorbidities, such
as cardiovascular diseases, are often re-
ported as the underlying cause of death
[8–10]. Similar discrepancies can also be
found for ischemicheartdisease, which is
oneof themost important causesof death
in Germany. According to data from the
GBD study, 202,017 people in Germany
(95%UI: 186,868–219,016) died from is-
chemic heart disease in 2015. The Ger-
man health reporting system, however,
identified 128,230 deaths for the same
ICD codes (I20–I25; [7]). One impor-
tant reason for the differences between
the GBD study data and official German
statistics is that the IHME performs cor-
rections of its vital statistics data. This
is particularly important in cases where
deaths were recorded using the wrong
ICD-10 codes or “garbage codes” (where
deaths are assigned to ICD-10 codes that
cannot have been related to the underly-
ing cause of death). The deviations can
causemarkeddifferencesinDALYswhich
illustrates the need for methodological
adjustments within a national burden of
disease study. During this project, differ-
ent data sources, including sources that
are not considered by the IHME, can be
analyzed and combined to produce im-
proved estimates of the burdenofdisease.
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Fig. 48 BURDEN2020 data holders anddata sources.Destatis Federal Statistical Office,WIdO Scien-
tific Institute of AOK,UBAGerman Environment Agency
Experience with European studies
of the national burden of disease
In addition to the fragmented data pool
and the fact that differences between the
GBD study and national statistics and
studies are sometimes hard to grasp, the
GBD study does not provide estimates
on sub-national level for many European
countries. In order to increase the exter-
nal validity and acceptance of the figures
provided by the IHME, several countries
have established their own studies on the
burden of disease. Some have conducted
their research (including the calculation
of sub-national estimates) in close coop-
eration with the IHME and have strictly
followed their methodology (this is the
casewithEngland andNorway; [11, 12]).
PublicHealthEnglandhasalreadyunder-
taken two assessments. Thefirstwas con-
ducted in 2013 and presented figures for
nine English regions and areas of social
deprivation [12]. The more recent 2016
study provided figures for 150 English
local authorities and is part of the GBD
2016 study [13]. Other countries have
already or are currently running their
own studies based on adapted method-
ologies (these include countries such as
the Netherlands, Scotland and Belgium)
[14–16]. The Dutch National Institute
of Public Health and the Environment
(RIVM) has long-standing experience in
performing burden of disease studies us-
ing its own approach. The 2018 report of
the Dutch Public Health Foresight Study
presented burden of disease estimates for
2015–2040basedonanupdatedmethod-
ologyandimproveddata [17]. Theresults
from the study provided information for
theDutchMinistryofHealth’s 4-yearpol-
icy plan.




The growing interest and use of the bur-
den of disease approach led to the ini-
tiation of BURDEN 2020 in Germany.
The project was preceded by a workshop
that took place in December 2015 [18]
and a secondworkshop that took place in
April 2018. Both workshops were used
to identify data requirements and to dis-
cuss methodological challenges together
with national and international experts
from the field. In addition, BURDEN
2020 also responds to challenges that
are emerging within the German health
system. The current attempts to imple-
menthealth reformsare facingchallenges
to ensure that health care planning be-
comes more closely geared to the mor-
bidity and disability patterns of the pop-
ulation and more responsive to regional
needs. The German health system cur-
rently lacks a decisive tool that could be
used to meet these demands: whereas
sub-national analyses of prevalence or
incidence of single diseases are available
[19–23], a comprehensive, non-interest-
guided presentation of the burden of dis-
ease, which would enable reliable and
regionalized analyses of public health is
not yet available. Thus, BURDEN 2020
is based on the assumption that ranking
individual diseases and risk factors ac-
cording to the impact that they have on
population health would provide a very
useful tool to policy makers and other
publichealth stakeholders. Furthermore,
the burden of disease approach is pre-
sumed to be sensitive to sub-national dif-
ferences and viewed as having the capac-
ity to generate immediate benefits for re-
gional health policy planning, evaluation
and implementation. Over the next three
years, BURDEN2020will pilot a national
burden of disease study for Germany. In
the future, this study is to be transformed
intoa tool thatenablescontinualdatapro-
cessing and visualization (. Fig. 2). This
is to be done by employing, modifying
and supplementing the methodology of
IHME in cooperation with international
partners so that it more closely reflects
the needs of health policy and planning
in Germany.
In order to achieve the objectives set
out above, in 2017, funding was ap-
plied for from the German Federal Joint
Committee’s Innovation Fund (Innova-
tionsausschuss beimGemeinsamenBun-
desausschuss), the application was ap-
proved in 2018 (Grant no. 01VSF17007).
For the pilot, BURDEN 2020 will focus
on a selected list of chronic conditions
and disease groups serving as model
conditions for chronic diseases of high
public health impact. The project will
take into account demographic devel-
opments that are marked by a clearly
defined spectrumof diseases, risk factors
and their consequences. These aspects
pose the main challenges for the future
development of the health care system
in Germany. The analyses are aimed at
initially calculating the disease burden
caused by ischemic heart disease, low
back and neck pain, stroke, tracheal,
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Fig. 58 Administrativeprevalenceofknowndementiabydistrictsandindependentcities inGermany
in 2016 (not adjusted for age andgender). Source: AOK claims data, own calculations
bronchial, and lung cancer, Alzheimer
disease and other dementias, diabetes,
chronic obstructive pulmonary disease
(COPD), falls, depressive disorders,
other cardiovascular and circulatory dis-
eases, colon and rectum cancer, anxiety
disorders, breast cancer, alcohol use dis-
orders, lower respiratory tract infections
(mainly pneumonia), hypertensive heart
disease and prostate cancer. The results
of the 2016 GBD study for Germany
show that a focus on these diseases will
cover at least a total of 51.9% of overall
DALYs that occur in the country. When
calculating mortality (deaths and YLL),
it should be straightforward enough to
extend this spectrum to achieve full cov-
erage of the IHME’s causes of death list.
The calculations on morbidity (preva-
lence and YLD), however, will initially
remain limited to selected diseases.
Partners, data and methodological
challenges
BURDEN 2020 is being jointly carried
out by three institutions (. Fig. 3). The
consortium is led by the Robert Koch
Institute (RKI) Department of Epidemi-
ology and Health Monitoring. The Sci-
entific Institute of the AOK (WIdO) and
theGermanEnvironmentAgency (UBA)
are equal partners. The project is accom-
panied by a scientific advisory board that
will be involved in important decisions
such as the selection of diseases and risk
factors and the regional level at which
estimates of burden of disease are feasi-
ble and appropriate. BURDEN 2020 is
also embedded in the European Burden
of Disease Network (EBoDN), a network
of WHO, IHME and national represen-
tatives with experience in the burden of
disease, which aims to promote scientific
debate and the exploration of method-
ological developments [24].
The project starts by calculating the
mortality associated with the burden of
disease. Individual data from cause of
death statistics in Germany held by the
Federal Statistical Office (Destatis) are
used for these mortality analyses. These
data contain information on age, gender,
place of residence and the underlying
cause of death. Thedata are accessible via
the Research Data Centres of the Federal
StatisticalOfficeandtheStatisticalOffices
of the Federal States (Länder); these data
also form the basis of the calculations of
the number of deaths and YLL (. Fig. 4).
The threeparticipating institutionsare
not only partners when it comes to mor-
bidity and risk factor analysis, but they
are also data holders and provide impor-
tant information for the assessment of
the national burden of disease (. Fig. 4).
As a scientific institute belonging to the
largest association of statutory health in-
surance providers in Germany, WIdO
holds data on around 26 million peo-
ple who are insured by the AOK (Allge-
meine Ortskrankenkasse). Anonymized
data including medical diagnoses, medi-
cal treatment, drugprescriptions anddis-
ease management programs enable the
assessment of the prevalence of diseases,
regional disaggregation and YLD [25].
Advantages of routine data even include
thepossibility todetect rarediseases, cap-
ture groups of the population that are
difficult to reach in surveys (like elderly
or people in institutions) and generate
information on the presence of comor-
bidities ormultimorbidity. Once the spe-
cific characteristics ofAOK insurees have
been accounted for, the results are to be
extrapolated to the German population
as a whole.
Furthermore, thehealth interviewand
examination surveys conducted by the
RKI as well as the German cancer reg-
istrydata constitute an important supple-
ment to claims data. Survey data enable
undiagnosed morbidity to be accounted
for as part of the calculations [26, 27].
Information on the number of people di-
agnosed with cancer that is provided by
the German Centre for Cancer Registry
Data [28] at the RKI will be used as an
additional data source for the calculation
of cancer prevalence.
It is essential that each of the se-
lected diseases and their sequelae are cor-
rectly defined for BURDEN 2020; how-
ever, defining disease using claims data
poses a challenge because the case se-
lection criteria that ultimately need to
be applied must be carefully tested and
brought in line with the definitions used
by the GBD study. This includes deci-
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Fig. 68 Current smokers according to gender (a female,bmale) and federal state, confidence intervals in brackets. (Source:
GEDA 2014/2015-EHIS [31])
sions as to whether the ICD codes used
in the GBD (on causes) can be retained
or should be adapted to the specific re-
quirements found in Germany. These
challenges mean that BURDEN 2020 has
to be initially limited to a selection of dis-
eases.
In general, BURDEN 2020 uses the
disability weights and severity distribu-
tions applied in the GBD study. It is
also planned that BURDEN 2020 takes
into account not just single diseases, but
also the comorbidities they are most fre-
quently associated with. Regarding the
severity of disease, the health interview
and examination surveys conducted by
the RKI may again constitute an impor-
tant supplement that enable empirical
measurements of severity distributions
that are more applicable to the situation
in Germany.
The data used to calculate the DALYs
are supplemented by information on the
distribution of risk factors in the popula-
tion. Behavioral risk factors will be ana-
lyzed based on the health interview and
examination surveys conducted by the
RKI, whereas environmental risk factors
will be analyzed using data from the Ger-
manEnvironmentAgency (UBA). Popu-
lation attributable fractions will indicate
which proportion of the disease burden
can be attributed to specific risk factors
(. Fig. 4). As a starting point, this is en-
visaged for smoking, tobacco consump-
tion, alcohol consumption, low levels of
physical activity and selected nutritional
risks as well as passive smoking, partic-
ulate matter, nitrogen dioxide and lead
exposure.
With respect to regional analyses [29],
the aim is to estimate disease burden at
a levelbelowthatofthe16Germanfederal
states as seen in. Fig. 5 for theprevalence
of dementia estimated from claims data.
Data are available for many indicators at
the federal state level (see the example for
current smokers in . Fig. 6), but it might
be challenging to break down the results
below this level. Nevertheless, there is
a fundamental need for regional infor-
mation when informing authorities and
other stakeholders and supporting the
planning of supply structures and pre-
vention. For example, there are 96 plan-
ningregionsinGermanyand401districts
and cities below the federal state level.
Taking into account aspects such as data
availability, data protection andmethod-
ological feasibility, BURDEN 2020 will
need to answer the question as to which
regional level is appropriate for estimates
of disease burden. In addition, the RKI’s
German Index of Socioeconomic Depri-
vation (GISD) offers the opportunity to
relate the regional burden of disease to
people’s living conditions [30].
Expected outcome
At the end of the project period, BUR-
DEN 2020 will provide the results of its
new, health-related data processing sys-
tem to the public. The merge of frag-
mented data sources will create a basis
with which to provide epidemiological
information and information for health
policy decisions. This includes a non-
interest-guided presentation of the bur-
den of disease (DALYs) in Germany and
its regions for a selection of what are
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predominantly non-communicable dis-
eases. Furthermore, it will also include
a presentation of the connection of the
burden of disease to a selected set of risk
factors. The calculations will be accessi-
ble free of charge via a permanent open
access informational infrastructure pro-
vided by the RKI, both electronically and
in the form of health reports and expert
contributions. Therefore, it will consti-
tute an information service for policy
makers and other public health stake-
holders. In the future, the project is to
be expanded to assess other diseases and
risk factors and its methodology is to
be tailored to the specific needs and de-
mands found inGermany. The long-term
goal is to provide a differentiated and
continuous calculation of disease bur-
den based on the available data in Ger-
many (. Fig. 2). Moreover, the project
is to enable forecasts and evaluations to
be made that deliver an appraisal of the
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